Anthony S. Fauci’s departure gives the Biden administration an opportunity to install the next generation of US leadership in biomedical research, but it must move swiftly with a Senate that’s losing some key NIH allies.
Fauci’s plan to step down in December after more than 50 years in government marks the end of a legendary career, advising seven presidents in his 38 years as director of the National Institute of Allergy and Infectious Diseases on outbreaks ranging from HIV to Covid-19.
“Now is the time to re-examine the portfolio and look for the kinds of leaders that can tackle the ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.